LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Strona główna・Stock List・CytoSorbents Corp
Search

CytoSorbents Corp

Closed

SectorHealthcare

0.39 -9.3

Neutral

Price update 10 cze 2026, 19:00 UTC

BuySell

Overview

Share price change

24h

Current

Min

0.39

Max

0.41

Key metrics

By Trading Economics

Income

368K

-5.1M

Sales

-370K

8.9M

EPS

-0.08

Profit margin

-57.863

Employees

129

EBITDA

648K

-3M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+78.57% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2026

Market Stats

By TradingEconomics

Market Cap

-14M

26M

Previous open

9.69

Previous close

0.39

News Sentiment

By Acuity

67%

33%

290 / 344 Ranking in Healthcare

CytoSorbents Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 cze 2026, 23:36 UTC

Earnings

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Read

10 cze 2026, 23:19 UTC

Hot Stocks

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Read

10 cze 2026, 23:09 UTC

Major Market Movers

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Read

10 cze 2026, 23:04 UTC

Earnings

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Read

10 cze 2026, 20:44 UTC

Major Market Movers

Caterpillar Raises Quarterly Dividend 8%

DJ

Read

10 cze 2026, 23:49 UTC

Acquisitions, Mergers, Takeovers

Elliott: Northern Star Should Take No Options Off The Table

DJ

Read

10 cze 2026, 23:48 UTC

Acquisitions, Mergers, Takeovers

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Read

10 cze 2026, 23:48 UTC

Acquisitions, Mergers, Takeovers

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Read

10 cze 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Read

10 cze 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Read

10 cze 2026, 23:46 UTC

Acquisitions, Mergers, Takeovers

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Read

10 cze 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Read

10 cze 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Read

10 cze 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Read

10 cze 2026, 21:57 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:52 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:35 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:22 UTC

Earnings

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Read

10 cze 2026, 20:39 UTC

Market Talk
Earnings

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Read

10 cze 2026, 20:34 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 20:33 UTC

Earnings

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Read

10 cze 2026, 20:33 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

DJ

Read

10 cze 2026, 20:33 UTC

Market Talk
Earnings

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Read

Peer Comparison

Price change

CytoSorbents Corp Forecast

Price Target

By TipRanks

78.57% upside

12 Months Forecast

Average 0.75 USD  78.57%

High 0.75 USD

Low 0.75 USD

Based on 1 Wall Street analysts offering 12 month price targets forCytoSorbents Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Based on 1 analysts giving stock ratings to CytoSorbents Corp - Dist in the past 3 months.

Sentiment

By Acuity

290 / 344 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Other stocks from the sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat